Reported data indicate that multicolor fluorescence imaging can be used for mapping heterogeneous breast cancer cells simultaneously and can distinguish targeted TNBC from non-targeted HER-2(+) or ER/PR(+) breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.